KEY POINTS
- This retrospective study from Fondazione Policlinico Universitario A. Gemelli, Rome, analyzed 85 patients with nasal vestibule carcinoma treated with high-dose-rate interventional radiotherapy between 2012 and 2026. The investigation focused on temporal changes in clinical target volume, catheter number and distribution, and dose non-uniformity ratio (DNR). It did not reassess local control, survival, cosmetic outcomes, or treatment-related toxicity, which were outside the objectives of this dosimetric analysis.
- HDR brachytherapy used interstitial or combined interstitial–endocavitary implantation techniques with an iridium-192 remote afterloader and TG-43-based planning. The reported prescription comprised 14 fractions, with 4 Gy in the first and final fractions and 3 Gy in each intermediate fraction, totaling 44 Gy. Catheter placement followed individual tumor anatomy rather than a fixed parallel or geometric arrangement, with implantation performed collaboratively by radiation oncologists and ENT surgeons.
- Implant complexity varied substantially across the cohort. Mean CTV volume was 25 cm³ (range 2–98 cm³), while the mean number of catheters was 10 (range 3–25). Mean dose non-uniformity ratio was 0.53 (range 0.30–0.78). Mean CTV V100% was 91.14% ± 9.21%, and mean CTV D90% was 103.04% ± 15.52% of the prescribed dose, reflecting substantial variation in anatomy and achievable coverage.
- Larger targets required more extensive catheter configurations. Over the 15-year institutional experience, mean CTV volumes increased, accompanied by an increase in the number of implanted catheters. Larger implants more frequently incorporated catheters positioned along the nasal packing, alar region, and upper lip rather than concentrating exclusively on the nasal septum. Mean CTV-to-catheter volume ratio was 2.38 cm³ per catheter, although patient-level variation was substantial.
- Dose heterogeneity decreased over time despite increasing implant complexity. The reported DNR showed a declining temporal trend, suggesting fewer high-dose regions relative to the adequately irradiated target volume. This finding was interpreted as evidence of progressively refined implantation and treatment planning. However, the study used descriptive trend analyses without formal hypothesis testing, so the magnitude and statistical certainty of any learning-curve effect remain unknown.
- Reported ocular doses were relatively low despite anatomically challenging target locations. Mean eye D2cm³, expressed as EQD2 using α/β = 3 Gy, was 6.54 ± 3.72 Gy for the ipsilateral eye and 5.23 ± 3.09 Gy for the contralateral eye. These values describe the analyzed plans and cannot independently establish low ocular toxicity risk without clinical outcome data or complete information about other relevant ocular substructures.
- The findings describe institutional technical evolution rather than validated treatment quality thresholds. The cohort was treated by a relatively stable team of radiation oncologists and ENT surgeons, and catheter designs evolved over time alongside anatomical selection and planning practice. No standardized comparator, interobserver assessment, or patient-level correlation between DNR and clinical toxicity was provided. Furthermore, the manuscript contains an apparent inversion in the written DNR formula, which should be clarified before using the reported values to establish quantitative planning criteria.
CLINICAL TAKEAWAY
Modern HDR brachytherapy for nasal vestibule carcinoma can accommodate anatomically complex targets through individualized catheter placement and increasingly refined implant geometry. This institutional experience suggests improved dose homogeneity despite larger treatment volumes, supporting careful multidisciplinary planning and dosimetric quality assurance. However, the results are descriptive and do not establish optimal catheter numbers, universal DNR constraints, or improved clinical outcomes.